<DOC>
	<DOCNO>NCT00002996</DOCNO>
	<brief_summary>RATIONALE : Flecainide therapy may help patient neuropathic pain live comfortably . PURPOSE : Phase II trial study effectiveness flecainide treat patient chronic neuropathic pain cancer AIDS .</brief_summary>
	<brief_title>Flecainide Treating Patients With Chronic Neuropathic Pain</brief_title>
	<detailed_description>OBJECTIVES : - Investigate effectiveness flecainide management neuropathic pain . OUTLINE : Patients give brief pain inventory ( BPI ) form ass pain upon enrollment study . Following 7 day stabilization period , flecainide administer . One capsule flecainide give twice day day 8-10 , two capsule give twice day day 11-14 three capsule give twice day day 15-21 . BPI form complete day 8 , 15 22 ass neuropathic pain . PROJECTED ACCRUAL : A total 7-20 patient accrue study .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Flecainide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Chronic neuropathic pain diagnosis cancer AIDS PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : SGOT great 2 time upper limit normal ( ULN ) Renal : Creatinine great 2 time ULN Cardiovascular : No clinical history infarction angina No advanced heart failure No sick sinus syndrome , intraventricular conduction disease , second third degree AV block arrhythmia require treatment ( exception may grant cardiac consult ) No focal wall motion abnormality Ejection fraction least 40 % Systolic blood pressure least 90 mm Hg Other : Must able take oral medication No known allergy adverse reaction flecainide , mexilitene type I antiarrhythmic drug Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 2 week since prior chemotherapy may cause neuropathy Endocrine therapy : At least 2 week since prior corticosteroid Radiotherapy : Not specify Surgery : Not specify Other : No tricyclic antidepressant treatment within past 2 week No concurrent use flecainide , mexiletene type I antiarrhythmic drug</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>pain</keyword>
</DOC>